TP53 and cancer: KRAS-Q61H is frequently co-mutated with TP53, and this co-alteration has been linked to increased genomic instability, invasion, and metastatic potential, particularly peritoneal dissemination, which is a feature shared with other cancers harboring KRAS-Q61H, such as pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).